

SHR-1701

Cat. No.:	HY-P99944
CAS No.:	2891860-17-4
Target:	PD-1/PD-L1; TGF- β Receptor
Pathway:	Immunology/Inflammation; TGF-beta/Smad
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	SHR-1701 (Retlirafusp alfa) is a bifunctional fusion protein targeting PD-L1 and TGF- β for cancer research ^[1] .
In Vitro	SHR-1701 (10 μ g/mL) can inhibit TGF- β signaling pathway, activate PI3K/Akt/Erk signaling pathway, rescue lymphocytes and restore the anti-tumor function of peripheral blood CD8 ⁺ T cells in patients with lung cancer ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Bo Cheng, et al. Anti-PD-L1/TGF- β R fusion protein (SHR-1701) overcomes disrupted lymphocyte recovery-induced resistance to PD-1/PD-L1 inhibitors in lung cancer. *Cancer Commun (Lond)*. 2022 Jan;42(1):17-36.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA